Appendix Figure 1. Analytical Framework

Key questions:

1. Is there direct evidence that systematic screening for type 2 diabetes, impaired fasting glucose, or impaired glucose tolerance among asymptomatic adults improves health outcomes?
2. Does beginning treatment of type 2 diabetes early as a result of screening provide an incremental benefit in health outcomes compared with initiating treatment after clinical diagnosis?
3. Does beginning treatment of impaired fasting glucose or impaired glucose tolerance early as a result of screening provide an incremental benefit in final health outcomes compared with initiating treatment after clinical diagnosis of type 2 diabetes?
4. What adverse effects result from screening a person for type 2 diabetes, impaired fasting glucose, or impaired glucose tolerance?
5. What adverse effects result from treating a person with type 2 diabetes, impaired fasting glucose, or impaired glucose tolerance detected by screening?

[D] Select for Text Description

Return to Document